SCHEMBL1421135

SCHEMBL1421135

CCOc1cc(/C=C2\SC(=S)N(c3ccc(F)nc3)C2=O)ccc1O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 12/20 0.61
KMT2A Q03164 12/20 0.61
MAPT P10636 7/20 0.61
CACNA1B Q00975 1/20 0.59
APBA1 Q02410 1/20 0.59
GRK6 P43250 1/20 0.59
FAAH O00519 1/20 0.59
POLB P06746 5/20 0.58
GAA P10253 3/20 0.58
FABP4 P15090 1/20 0.58
ALDH1A1 P00352 4/20 0.57
RECQL P46063 3/20 0.57
THRB P10828 2/20 0.57
NPC1 O15118 1/20 0.57
ALOX12 P18054 1/20 0.57
NPSR1 Q6W5P4 1/20 0.57
TDP1 Q9NUW8 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.57
MAPK1 P28482 3/20 0.55
OPRK1 P41145 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1421138 1.00 MEN1 (0.61) MEN1KMT2AMAPTCACNA1BAPBA1
SCHEMBL1421482 0.89 FAAH (0.73) MEN1KMT2AMAPTCACNA1BAPBA1
SCHEMBL1421478 0.89 FAAH (0.73) MEN1KMT2AMAPTCACNA1BAPBA1
SCHEMBL12726855 0.85 MEN1 (0.70) MEN1KMT2AMAPTCACNA1BAPBA1
SCHEMBL1421441 0.85 KMT2A (0.81) MEN1KMT2AMAPTCACNA1BAPBA1
SCHEMBL1421437 0.85 KMT2A (0.81) MEN1KMT2AMAPTCACNA1BAPBA1
SCHEMBL1421134 0.85 MEN1 (0.61) MEN1KMT2AMAPTCACNA1BAPBA1
SCHEMBL1421130 0.85 MEN1 (0.61) MEN1KMT2AMAPTCACNA1BAPBA1
SCHEMBL1421133 0.85 MEN1 (0.61) MEN1KMT2AMAPTCACNA1BAPBA1
SCHEMBL1421490 0.85 MEN1 (0.68) MEN1KMT2AMAPTCACNA1BAPBA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098323-A1 INHIBITORS OF BACTERIAL BIOFILM FORMATION MICROBIOTIX, INC. (US) 2011-04-28 US disclosed
US-20110098323-A1 INHIBITORS OF BACTERIAL BIOFILM FORMATION MICROBIOTIX, INC. (US) 2011-04-28 US disclosed
US-20110098323-A1 INHIBITORS OF BACTERIAL BIOFILM FORMATION MICROBIOTIX, INC. (US) 2011-04-28 US disclosed
EP-2296476-A1 INHIBITORS OF BACTERIAL BIOFILM FORMATION Microbiotix, Inc. (US) 2011-03-23 EP disclosed
WO-2009142720-A1 INHIBITORS OF BACTERIAL BIOFILM FORMATION MICROBIOTIX, INC. (US) 2009-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098323-A1 INHIBITORS OF BACTERIAL BIOFILM FORMATION BLVRB, TFPI, FOSB MEN1 4836/4885KMT2A 3896/4885MAPT 4065/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.